Literature DB >> 23085057

Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer.

Sigrid V Carlsson1, Laura J Tafe, Daher C Chade, Daniel D Sjoberg, Niccolo Passoni, Shahrokh F Shariat, James Eastham, Peter T Scardino, Samson W Fine, Karim A Touijer.   

Abstract

PURPOSE: Subclassification of nodal stage may have prognostic value in men with lymph node metastasis at radical prostatectomy. We explored the role of extranodal extension, size of the largest metastatic lymph node and the largest metastasis, and lymph node density as predictors of biochemical recurrence.
MATERIALS AND METHODS: We reviewed pathological material from 261 patients with node positive prostate cancer. We examined the predictive value when adding the additional pathology findings to a base model including extraprostatic extension, seminal vesicle invasion, radical prostatectomy Gleason score, prostate specific antigen and number of positive lymph nodes using the Cox proportional hazards regression and Harrell concordance index.
RESULTS: The median number of lymph nodes removed was 14 (IQR 9, 20) and the median number of positive lymph nodes was 1 (IQR 1, 2). At a median followup of 4.6 years (IQR 3.2, 6.0) 155 of 261 patients experienced biochemical recurrence. The mean 5-year biochemical recurrence-free survival rate was 39% (95% CI 33-46). Median diameter of the largest metastatic lymph node was 9 mm (IQR 5, 16). On Cox regression radical prostatectomy specimen Gleason score (greater than 7 vs 7 or less), number of positive lymph nodes (3 or greater vs 1 or 2), seminal vesicle invasion and prostate specific antigen were associated with significantly increased risks of biochemical recurrence. On subset analysis metastasis size significantly improved model discrimination (base model Harrell concordance index 0.700 vs 0.655, p = 0.032).
CONCLUSIONS: Our study confirms that the number of positive lymph nodes is a predictor of biochemical recurrence in men with node positive disease. The improvement in prognostic value of measuring the metastatic focus warrants further investigation.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23085057      PMCID: PMC4166648          DOI: 10.1016/j.juro.2012.10.027

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

1.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

2.  Clinical importance of lymph node density in predicting outcome of prostate cancer patients.

Authors:  Tommaso Cai; Gabriella Nesi; Galliano Tinacci; Gianluca Giubilei; Andrea Gavazzi; Nicola Mondaini; Enzo Zini; Riccardo Bartoletti
Journal:  J Surg Res       Date:  2009-06-06       Impact factor: 2.192

Review 3.  Staging of prostate cancer.

Authors:  Liang Cheng; Rodolfo Montironi; David G Bostwick; Antonio Lopez-Beltran; Daniel M Berney
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

Review 4.  Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome.

Authors:  Julia Adams; Liang Cheng
Journal:  Expert Rev Anticancer Ther       Date:  2011-09       Impact factor: 4.512

5.  Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.

Authors:  Siamak Daneshmand; Marcus L Quek; John P Stein; Gary Lieskovsky; Jie Cai; Jacek Pinski; Eila C Skinner; Donald G Skinner
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

6.  Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987.

Authors:  G D Steinberg; J I Epstein; S Piantadosi; P C Walsh
Journal:  J Urol       Date:  1990-12       Impact factor: 7.450

7.  Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer.

Authors:  T L Griebling; D Ozkutlu; W A See; M B Cohen
Journal:  Mod Pathol       Date:  1997-08       Impact factor: 7.842

8.  Cancer volume of lymph node metastasis predicts progression in prostate cancer.

Authors:  L Cheng; E J Bergstralh; J C Cheville; J Slezak; F A Corica; H Zincke; M L Blute; D G Bostwick
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

9.  Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy.

Authors:  A R Sgrignoli; P C Walsh; G D Steinberg; M S Steiner; J I Epstein
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450

10.  Prostate cancer topography and patterns of lymph node metastasis.

Authors:  Yuji Tokuda; Lauren J Carlino; Anuradha Gopalan; Satish K Tickoo; Matthew G Kaag; Bertrand Guillonneau; James A Eastham; Howard I Scher; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2010-12       Impact factor: 6.394

View more
  11 in total

1.  Specific spatial distribution patterns of tumor foci are associated with a low risk of biochemical recurrence in pT2pN0R0 prostate cancer.

Authors:  Okyaz Eminaga; Mahmoud Abbas; Olaf Bettendorf; Axel Semjonow
Journal:  World J Urol       Date:  2020-06-26       Impact factor: 4.226

Review 2.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

3.  Prostate cancer: lymph node metastases: not always the same prognosis.

Authors:  Riccardo Schiavina; Eugenio Brunocilla
Journal:  Nat Rev Urol       Date:  2013-06-11       Impact factor: 14.432

4.  Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy.

Authors:  Piotr Zareba; James Eastham; Peter T Scardino; Karim Touijer
Journal:  J Urol       Date:  2017-06-15       Impact factor: 7.450

5.  Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.

Authors:  Melissa J Assel; Hans David Ulmert; R Jeffery Karnes; Stephen A Boorjian; David W Hillman; Andrew J Vickers; George G Klee; Hans Lilja
Journal:  Prostate       Date:  2019-10-11       Impact factor: 4.104

6.  Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy.

Authors:  Avinash Chenam; Jaspreet S Parihar; Nora Ruel; Sumanta Pal; Yvonne Avila; Jonathan Yamzon; Clayton Lau; Bertram Yuh
Journal:  J Robot Surg       Date:  2017-09-13

7.  Clinicopathological Analysis of the ISUP Grade Group And Other Parameters in Prostate Cancer: Elucidation of Mutual Impact of the Various Parameters.

Authors:  Yoichiro Okubo; Shinya Sato; Kimito Osaka; Yayoi Yamamoto; Takahisa Suzuki; Arika Ida; Emi Yoshioka; Masaki Suzuki; Kota Washimi; Tomoyuki Yokose; Takeshi Kishida; Yohei Miyagi
Journal:  Front Oncol       Date:  2021-07-28       Impact factor: 6.244

8.  Prognostic Features of Near-Infrared Spectroscopy Following Primary Radical Prostatectomy.

Authors:  Tijl Vermassen; Jonas Himpe; Renaat Coopman; Charles Van Praet; Nicolaas Lumen; Sylvie Rottey; Joris Delanghe
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

9.  Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes.

Authors:  Xi Hong; Liang Mao; Luwei Xu; Qiang Hu; Ruipeng Jia
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

10.  Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment.

Authors:  L A Kluth; F Abdollah; E Xylinas; M Rieken; H Fajkovic; C Seitz; M Sun; P I Karakiewicz; P Schramek; M P Herman; A Becker; J Hansen; B Ehdaie; W Loidl; K Pummer; R K Lee; Y Lotan; D S Scherr; D Seiler; S A Ahyai; F K-H Chun; M Graefen; A Tewari; A Nonis; A Bachmann; F Montorsi; M Gönen; A Briganti; S F Shariat
Journal:  Br J Cancer       Date:  2014-07-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.